Growth hormone–releasing peptide
Compounded Sermorelin injection
A separate hormone-related topic. Understanding why sermorelin came up is the first question to bring to a clinician.

Compounded medicines are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before marketing. Package images are illustrations. Read the FDA’s guidance.
Understand the distinction
Sermorelin stimulates the release of growth hormone. Its mechanism differs from GLP-1 treatments. Its historical US approval concerned a specific childhood growth disorder and does not establish a weight-management benefit.
Ask about the evidence
If sermorelin appears alongside weight-care options, ask the clinician to name the condition being assessed. Ask which evidence applies to people with that condition and which alternatives they would consider.
Clarify the product
Ask for the exact formulation, who prepares it and what follow-up would involve. A historical approval for one product does not confer approval on a newly compounded preparation.
Explore other injectables

Injection
Compounded Tirzepatide injection
Learn which product your clinician is discussing, why they are considering it and how they would review your progress.

Injection
Compounded Semaglutide injection
An ingredient may appear in several products. Start with the prescription name and the reason your clinician is considering it.